{"title":"Fenoterol solution via nebuliser--optimum dosage.","authors":"A V Harries, C M Laroche, M G Britton","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>We report the results of a double-blind controlled study of 20 asthmatic patients to determine the optimum dose of fenoterol given by nebuliser. Lung function was monitored after four different doses (0.5 mg, 1.25 mg, 2.5 mg, 5 mg) and placebo. All four doses of fenoterol were found to be significantly superior to placebo. Doses of 5 mg and 2.5 mg were also significantly more effective than the 0.5 mg dose up to 3 h. There was no significant difference between the three highest doses. In this study of relatively stable asthmatics, the increased bronchodilatation obtained with the higher doses of fenoterol (5 mg and 2.5 mg) was not sufficient to offset the higher incidence of side-effects, and we therefore recommend 1.25 mg as a starting dose. Higher doses may be needed for severely ill patients in whom side-effects are not such an important consideration.</p>","PeriodicalId":12053,"journal":{"name":"European journal of respiratory diseases","volume":"71 5","pages":"334-8"},"PeriodicalIF":0.0000,"publicationDate":"1987-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of respiratory diseases","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
We report the results of a double-blind controlled study of 20 asthmatic patients to determine the optimum dose of fenoterol given by nebuliser. Lung function was monitored after four different doses (0.5 mg, 1.25 mg, 2.5 mg, 5 mg) and placebo. All four doses of fenoterol were found to be significantly superior to placebo. Doses of 5 mg and 2.5 mg were also significantly more effective than the 0.5 mg dose up to 3 h. There was no significant difference between the three highest doses. In this study of relatively stable asthmatics, the increased bronchodilatation obtained with the higher doses of fenoterol (5 mg and 2.5 mg) was not sufficient to offset the higher incidence of side-effects, and we therefore recommend 1.25 mg as a starting dose. Higher doses may be needed for severely ill patients in whom side-effects are not such an important consideration.